Acumen Pharmaceuticals(ABOS) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights NEWTON, Mass., Nov. 12, 2025 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the third quarter of 2025 and provided a business update. "We continued our strong operati ...